EXPRESSION OF P53 OR CYTOPLASMIC NUCLEOPHOSMINE ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION IN MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5Q)

被引：0
|
作者：
Jadersten, M. S. [1 ]
Saft, L. [1 ]
Garelius, H. [2 ]
Hast, R. [1 ]
Nilsson, L. [3 ]
Samuelsson, J. [4 ]
Porwit, A. [1 ]
Hellstrom-Lindberg, E. [1 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Sahlgrens Univ Hosp, Gothenburg, Sweden
[3] Univ Lund Hosp, S-22185 Lund, Sweden
[4] Soder Sjukhuset, Stockholm, Sweden
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0257
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [31] HYPOPLASTIC MYELODYSPLASTIC SYNDROME, HYPERPLASTIC AND WITH ISOLATED ABNORMAL 5Q: DIFFERENCES IN CLINICAL AND MUTATIONAL RISK PROFILE
    Rodriguez, Gil Miguel Angel
    Hernandez, Mohedo Francisca
    Bernal, Sanchez Monica
    Hermosin, Ramos Lourdes
    Sanchez, Garcia Joaquin
    Jerez, Cayuela Andres
    Munoz, Novas Carolina
    Sanchez, De Puerta Maria Vahi
    Bernal, Del Castillo Teresa
    Cornejo, Calvo Maria Elena
    Cruz, Diaz Antonio Jesus
    Palomo, Sanchis Laura
    Exposito, Ruiz Manuela
    Jurado, Chacon Manuel
    HAEMATOLOGICA, 2020, 105 : 76 - 76
  • [32] The expression of P53 makes it possible to predict the evolution of patients with low-risk myelodysplasia with deletion 5q
    Eclache, Virginie
    HEMATOLOGIE, 2014, 20 (03): : 136 - 137
  • [33] Tifab, a Del(5q) MDS/AML Gene, Regulates USP15 Activity and p53
    Niederkorn, Madeline
    Varney, Melinda
    Smith, Molly A.
    Meetei, Ruhikanta A.
    Starczynowski, Daniel T.
    BLOOD, 2016, 128 (22)
  • [34] Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
    S Wei
    X Chen
    K McGraw
    L Zhang
    R Komrokji
    J Clark
    G Caceres
    D Billingsley
    L Sokol
    J Lancet
    N Fortenbery
    J Zhou
    E A Eksioglu
    D Sallman
    H Wang
    P K Epling-Burnette
    J Djeu
    M Sekeres
    J P Maciejewski
    A List
    Oncogene, 2013, 32 : 1110 - 1120
  • [35] Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
    Wei, S.
    Chen, X.
    McGraw, K.
    Zhang, L.
    Komrokji, R.
    Clark, J.
    Caceres, G.
    Billingsley, D.
    Sokol, L.
    Lancet, J.
    Fortenbery, N.
    Zhou, J.
    Eksioglu, E. A.
    Sallman, D.
    Wang, H.
    Epling-Burnettel, P. K.
    Djeu, J.
    Sekeres, M.
    Maciejewski, J. P.
    List, A.
    ONCOGENE, 2013, 32 (09) : 1110 - 1120
  • [36] HIGH P53 PROTEIN EXPRESSION IS ASSOCIATED WITH WT1 MRNA LEVEL AND DISEASE STAGE PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME.
    Yamazaki, E.
    Enaka, M.
    Koyama, S.
    Takahashi, H.
    Nakajima, Y.
    Miyazaki, T.
    Tachibana, T.
    Ohashi, K.
    Tomita, N.
    Ishigatsubo, Y.
    HAEMATOLOGICA, 2015, 100 : 722 - 723
  • [37] Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation
    Nomdedeu, Meritxell
    Maffioli, Margherita
    Calvo, Xavier
    Martinez-Trillos, Alejandra
    Baumann, Tycho
    Diaz-Beya, Marina
    Aguilar, Josep-Lluis
    Rozman, Maria
    Costa, Dolors
    Esteve, Jordi
    Cervantes, Francisco
    Colomer, Dolors
    Nomdedeu, Benet
    LEUKEMIA RESEARCH, 2011, 35 (09) : 1276 - 1278
  • [38] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    G Göhring
    K Lange
    W Hofmann
    K V Nielsen
    E Hellström-Lindberg
    L Roy
    M Morgan
    H Kreipe
    G Büsche
    A Giagounidis
    B Schlegelberger
    Leukemia, 2012, 26 : 356 - 358
  • [39] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    Goehring, G.
    Lange, K.
    Hofmann, W.
    Nielsen, K. V.
    Hellstrom-Lindberg, E.
    Roy, L.
    Morgan, M.
    Kreipe, H.
    Buesche, G.
    Giagounidis, A.
    Schlegelberger, B.
    LEUKEMIA, 2012, 26 (02) : 356 - 358
  • [40] High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide
    Jonasova, Anna T.
    Polak, Jaroslav
    Vostry, Martin
    Kostecka, Arnost
    Bokorova, Radka
    Neuwirtova, Radana
    Siskova, Magda
    Caniga, Miroslav
    Sponerova, Dana
    Cermak, Jaroslav
    Mikulenkova, Dana
    Brezinova, Jana
    Michalova, Kyra
    Fuchs, Ota
    BLOOD, 2013, 122 (21)
12345